2025-06-04Niranjan Ghatule
Sun Pharma Advanced Research Company (SPARC) shares hit a 20% lower circuit after its much-hyped drug candidate SCD-044 failed in Phase 2 clinical trials. The management had earlier given a strong positive commentary about the drug’s potential, calling it a game-changer.
View more
Your experience on this site will be improved by allowing cookies
Cookie Policy
